Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2019-02-12 Major Shareholding Noti…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-12 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-11 English
PRIMARY DOCUMENT
Director's Dealing
2019-02-08 English
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2019, reporting the issuance of a press release announcing financial results for the three and twelve months ended December 31, 2018. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K is a current report. The document does not contain the full financial results or detailed financial statements but rather announces the results via a press release. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. The document length is 3620 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. Therefore, the correct classification is Earnings Release (ER).
2019-02-07 English
8-K_2.7.19
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text describes a licensing agreement entered into by the company, including details about the agreement terms and payments. It does not contain financial statements or detailed financial analysis, nor is it an annual or quarterly report. It is not a proxy, earnings release, or management discussion. The document length is 3145 characters, which is relatively short and typical for an 8-K filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like 8-Ks that do not fit other specific categories.
2019-02-07 English
8-K_1.28.19
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 23, 2019, by Ligand Pharmaceuticals Incorporated. The content describes an increase in the company's share repurchase program, including details about the authorization amount, expiration date, and shares acquired. There are no financial statements or detailed financial analysis present, only an announcement of a capital activity (share repurchase program increase). The document is about a financing/capital structure update rather than a full financial report or earnings release. Therefore, it fits best under the category for Capital/Financing Update (CAP). The document length is 4705 characters, which is sufficient for a substantive announcement but not a full report. Hence, the classification is CAP with high confidence.
2019-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.